AI Image
GLP-1 drugs carry risk of rare but serious eye condition
The Conversation • • business
Key Points:
- The U.S. FDA has mandated warning labels on GLP-1 drugs due to a potential link to a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss.
- Studies, including one involving nearly 17,000 patients and data from over 134,000 clinical trial participants, indicate a small but increased risk of NAION in patients taking GLP-1 medications compared to placebo or other diabetes drugs.
- Real-world data from large populations, such as U.S. veterans with type 2 diabetes, corroborate the association, showing approximately 100 additional cases of NAION per 100,000 patients on GLP-1 drugs versus alternative treatments.
- The risk of NAION appears consistent across different GLP-1 drugs, with no current evidence suggesting one drug poses a higher risk than others, and European regulators have similarly updated warnings for semaglutide.
- Despite the low incidence, clinicians are advised to inform patients about this rare but serious side effect and educate them on NAION symptoms, ensuring informed decisions when prescribing GLP-1 drugs for diabetes or obesity.
![If you bought an iPhone Duo, have you kept or returned it? [Poll]](https://media-cdn.cashwalklabs.io/https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fimages.cashwalklabs.io%2F0_admin%2Fnews-ai-images%2F01a1cb91-fbfd-752c-9444-39f022e668ff.webp?format=webp&w=120&h=80)
